New dengue vaccine shows promise in early trial
NCT ID NCT03746015
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tested a tetravalent dengue vaccine (TDV) in 30 healthy adults, some with prior dengue exposure and some without. The goal was to measure the body's immune response and check for safety. Participants received a single shot, and researchers tracked antibody levels over 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tetravalent Dengue Vaccine (TDV) – a shot containing weakened versions of all four dengue virus types
What this could lead to
If successful, this vaccine could help protect people from all four types of dengue fever, reducing the risk of severe illness.
What could go wrong
This is a small, early-phase trial with only 30 participants. The vaccine may not produce strong enough immunity or may have side effects. Larger studies are needed to confirm safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DENGUE FEVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Optimal Research
Peoria, Illinois, 61614, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States